(Q52893441)

9 May 2018

title

Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. (English)

1 reference

9 May 2018

author name string

Addolorato G

1

1 reference

9 May 2018

Caputo F

2

1 reference

9 May 2018

Capristo E

3

1 reference

9 May 2018

Colombo G

4

1 reference

9 May 2018

Gessa GL

5

1 reference

9 May 2018

Gasbarrini G

6

1 reference

9 May 2018

publication date

1 January 2000

1 reference

9 May 2018

Alcoholism: Clinical and Experimental Research

published in

1 reference

9 May 2018

volume

24

1 reference

9 May 2018

issue

1

1 reference

9 May 2018

page(s)

67-71

1 reference

9 May 2018

An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Maintaining abstinence from alcohol with gamma-hydroxybutyric acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Gamma-hydroxybutyric acid in the treatment of alcoholism: dosage fractioning utility in non-responder alcoholic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

A new alcohol antagonist: phaclofen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Symmetrical generalization between the discriminative stimulus effects of gamma-hydroxybutyric acid and ethanol: occurrence within narrow dose ranges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Involvement of GABA(A) and GABA(B) receptors in the mediation of discriminative stimulus effects of gamma-hydroxybutyric acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

GABA transmission, but not benzodiazepine receptor stimulation, modulates ethanol intake by rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Antispasticity drugs: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Review of neurotransmitters and their role in alcoholism treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Baclofen administration for the treatment of affective disorders in alcoholic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Baclofen as a cocaine anti-craving medication: a preliminary clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Drug therapy for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

gamma-Hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Gamma-hydroxybutyric acid reducing effect on ethanol intake: evidence in favour of a substitution mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Outcome studies of brief alcohol intervention in general practice: the problem of lost subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

Comparison of acamprosate and placebo in long-term treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2000.TB04555.X

10.1111/J.1530-0277.2000.TB04555.X

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018